Stock Events

Stock Events

Ascendis Pharma A/S 

$250.14
59
+$0.59+0.24%Tuesday 08:44

Statistics

Day High
250.14
Day Low
250.14
52W High
275.83
52W Low
206.47
Volume
1
Avg. Volume
-
Mkt Cap
16.46B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 11Expected
Q4 2025
Q1 2026
Q2 2026
Next
-0.65
3.32
7.29
11.26
Expected EPS
0.89374052392
Actual EPS
N/A

Financials

-31.32%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.68BRevenue
-526.7MNet Income

Analyst Ratings

$314.13Average Price Target
The highest estimate is ⁦344.00⁩.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ASND.BOATS. It's not an investment recommendation.
NVIDIA
13
NVDA
Microsoft
12
MSFT
Apple
8
AAPL
Meta Platforms
8
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap173.95B
Pfizer competes in various therapeutic areas including those targeted by Ascendis Pharma's endocrinology and oncology pipeline.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk is a leader in diabetes and growth disorders, directly competing with Ascendis Pharma's growth hormone deficiency treatments.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly has a strong presence in endocrinology, particularly in growth hormone and diabetes treatments, competing with Ascendis' portfolio.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals competes in the development of treatments for genetic disorders, a key area of focus for Ascendis Pharma.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical focuses on rare diseases, including areas like growth disorders, directly competing with Ascendis' therapies.
Opko Health
OPK
Mkt Cap1.24B
OPKO Health has a division focused on pharmaceuticals, including growth hormone treatments, making it a direct competitor.
Ligand Pharmaceuticals
LGND
Mkt Cap6.43B
Ligand Pharmaceuticals' technology platforms and partnerships enable it to compete in the development of endocrinology and oncology drugs.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes in the biopharmaceutical space with a focus on innovative treatments, overlapping with Ascendis' therapeutic areas.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurological and neurodegenerative diseases but its expansion into other biopharmaceutical areas can position it as a competitor.
AMGEN
AMGN
Mkt Cap251.94B
Amgen's broad focus on biotechnology treatments for various diseases, including bone health and oncology, places it in competition with Ascendis Pharma.

About

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Show More
CEO
ISIN
US04351P1012

Listings

SA
BR
A1SN34.SA
MX
MX
ASND1N.MX
STU
DE
A71.STU
MU
DE
A710.MU

0 Comments

Share your thoughts

FAQs

What is Ascendis Pharma A/S stock price today?▼
The current price of ASND.BOATS is $250.14 USD — it has increased by +0.24% in the past 24 hours. Watch Ascendis Pharma A/S stock price performance more closely on the chart.
What is Ascendis Pharma A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Ascendis Pharma A/S stocks are traded under the ticker ASND.BOATS.
What is Ascendis Pharma A/S market cap?▼
Today Ascendis Pharma A/S has the market capitalization of 16.46B
When is the next Ascendis Pharma A/S earnings date?▼
Ascendis Pharma A/S is going to release the next earnings report on November 11, 2026.
What were Ascendis Pharma A/S earnings last quarter?▼
ASND.BOATS earnings for the last quarter are 3.23 USD per share, whereas the estimation was 1.71 USD resulting in a +89.09% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ascendis Pharma A/S revenue for the last year?▼
Ascendis Pharma A/S revenue for the last year amounts to 1.68B USD.
What is Ascendis Pharma A/S net income for the last year?▼
ASND.BOATS net income for the last year is -526.7M USD.
In which sector is Ascendis Pharma A/S located?▼
Ascendis Pharma A/S operates in the Other sector.
When did Ascendis Pharma A/S complete a stock split?▼
Ascendis Pharma A/S has not had any recent stock splits.